The impact of vaccination and SARS-CoV-2 variants on the virological response to SARS-CoV-2 infections during the Alpha, Delta, and Omicron waves in England
Copyright © 2023. Published by Elsevier Ltd..
Vaccination status and the SARS-CoV-2 variant individuals are infected with are known to independently impact viral dynamics; however, little is known about the interaction of these two factors and how this impacts viral dynamics. Here we investigated how monovalent vaccination modified the time course and viral load of infections from different variants. Regression analyses were used to investigate the impact of vaccination on cycle threshold values and disease severity, and interval-censored survival analyses were used to investigate the impact of vaccination on duration of positivity. A range of covariates were adjusted for as potential confounders and investigated for their own effects in exploratory analyses. All analyses were done combining all variants and stratified by variant. For those infected with Alpha or Delta, vaccinated individuals were more likely to report mild disease than moderate/severe disease and had significantly shorter duration of positivity and lower viral loads compared to unvaccinated individuals. Vaccination had no impact on self-reported disease severity, viral load, or duration if positivity for those infected with Omicron. Overall, individuals who were immunosuppressed and clinically extremely vulnerable had longer duration of positivity and higher viral loads. This study adds to the evidence base on disease dynamics following COVID-19, demonstrating that vaccination mitigates severity of disease, the amount of detectable virus within infected individuals and reduces the time individuals are positive for. However, these effects have been significantly attenuated since the emergence of Omicron. Therefore, our findings strengthen the argument for using modified or multivalent vaccines that target emerging variants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:88 |
|---|---|
| Enthalten in: |
The Journal of infection - 88(2024), 1 vom: 04. Jan., Seite 21-29 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lunt, Rachel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cycle threshold (Ct) values |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 08.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2023.10.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364179643 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364179643 | ||
| 003 | DE-627 | ||
| 005 | 20240114232011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2023.10.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1252.xml |
| 035 | |a (DE-627)NLM364179643 | ||
| 035 | |a (NLM)37926118 | ||
| 035 | |a (PII)S0163-4453(23)00547-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lunt, Rachel |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The impact of vaccination and SARS-CoV-2 variants on the virological response to SARS-CoV-2 infections during the Alpha, Delta, and Omicron waves in England |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 08.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Ltd. | ||
| 520 | |a Vaccination status and the SARS-CoV-2 variant individuals are infected with are known to independently impact viral dynamics; however, little is known about the interaction of these two factors and how this impacts viral dynamics. Here we investigated how monovalent vaccination modified the time course and viral load of infections from different variants. Regression analyses were used to investigate the impact of vaccination on cycle threshold values and disease severity, and interval-censored survival analyses were used to investigate the impact of vaccination on duration of positivity. A range of covariates were adjusted for as potential confounders and investigated for their own effects in exploratory analyses. All analyses were done combining all variants and stratified by variant. For those infected with Alpha or Delta, vaccinated individuals were more likely to report mild disease than moderate/severe disease and had significantly shorter duration of positivity and lower viral loads compared to unvaccinated individuals. Vaccination had no impact on self-reported disease severity, viral load, or duration if positivity for those infected with Omicron. Overall, individuals who were immunosuppressed and clinically extremely vulnerable had longer duration of positivity and higher viral loads. This study adds to the evidence base on disease dynamics following COVID-19, demonstrating that vaccination mitigates severity of disease, the amount of detectable virus within infected individuals and reduces the time individuals are positive for. However, these effects have been significantly attenuated since the emergence of Omicron. Therefore, our findings strengthen the argument for using modified or multivalent vaccines that target emerging variants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cycle threshold (Ct) values | |
| 650 | 4 | |a Duration of positivity | |
| 650 | 4 | |a Viral load | |
| 700 | 1 | |a Quinot, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Kirsebom, Freja |e verfasserin |4 aut | |
| 700 | 1 | |a Andrews, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Skarnes, Catriona |e verfasserin |4 aut | |
| 700 | 1 | |a Letley, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Haskins, Donna |e verfasserin |4 aut | |
| 700 | 1 | |a Angel, Catriona |e verfasserin |4 aut | |
| 700 | 1 | |a Firminger, Skye |e verfasserin |4 aut | |
| 700 | 1 | |a Ratcliffe, Kay |e verfasserin |4 aut | |
| 700 | 1 | |a Rajan, Shelina |e verfasserin |4 aut | |
| 700 | 1 | |a Sherridan, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Ijaz, Samreen |e verfasserin |4 aut | |
| 700 | 1 | |a Zambon, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Ramsay, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Bernal, Jamie Lopez |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 88(2024), 1 vom: 04. Jan., Seite 21-29 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:88 |g year:2024 |g number:1 |g day:04 |g month:01 |g pages:21-29 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2023.10.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 88 |j 2024 |e 1 |b 04 |c 01 |h 21-29 | ||